(NASDAQ: CAI) Caris Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.88%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.15%.
Caris Life Sciences's revenue in 2026 is N/A.On average, 11 Wall Street analysts forecast CAI's revenue for 2026 to be $280,468,148,808, with the lowest CAI revenue forecast at $260,190,249,452, and the highest CAI revenue forecast at $301,897,207,610. On average, 10 Wall Street analysts forecast CAI's revenue for 2027 to be $342,244,217,599, with the lowest CAI revenue forecast at $313,747,378,376, and the highest CAI revenue forecast at $367,637,440,669.
In 2028, CAI is forecast to generate $399,802,189,891 in revenue, with the lowest revenue forecast at $345,347,833,752 and the highest revenue forecast at $440,995,640,649.